Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Prognostic impact of CAR-T cell expansion and PD1 expression in patients with DLBCL treated with axicabtagene ciloleucel

View Full Paper
Ask AI
Bookmark
Share

Authors

DCDiego CarbonellIGIgnacio Gómez‐CenturiónPSPablo Silva

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds significant cumulative incidence of progression-free survival in DLBCL patients after CAR-T infusion, indicating the prognostic value of peripheral blood analysis.

Key Points

  • Cumulative incidence of progression-free survival for DLBCL patients after CAR-T therapy was assessed in peripheral blood samples.
  • At day 28 post-infusion, the cumulative incidence of cytokine release syndrome was 95.2% for any grade among patients.
  • The analysis revealed that a higher CAR-T expansion in peripheral blood is associated with improved outcomes.
  • Findings suggest that monitoring CAR-T parameters may enable better prognosis and tailored treatment in DLBCL.

Cite This Study

Carbonell et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e267https://doi.org/10.1182/blood-2025-5503
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8‑color flow cytometry panel reveals substantial differences among products kinetics and persistence2025 · 1 citations
  2. 2Real-world analysis of axicabtagene ciloleucel (axi-cel) as consolidation therapy following first-line treatment in B-cell lymphoma with high-risk factors2025
  3. 3Lymphocyte kinetics as a predictor of clinical outcomes following CAR-T therapy for non-Hodgkin lymphoma2025
  4. 4Circulating CD161high CD8 T cells at leukapheresis are associated with reduced risk of progression at 12 months (PFS12) in large B-cell lymphoma treated by axicabtagene ciloleucel: Results from the Phase 2 alycante study (LYSA)2025
  5. 5Pre-manufacturing CD8+ central-memory type 2 T cells predict axicabtagene ciloleucel failure in large B-cell lymphoma2025